Amphotericin B and fluconazole affect cellular charge, macrophage phagocytosis, and cellular morphology of Cryptococcus neoformans at subinhibitory concentrations

Antimicrobial Agents and Chemotherapy

Volumn 43, Issue 2, 1999, Pages 233-239

  Nosanchuk, Joshua D ^a   Cleare, Wendy ^a   Franzot, Sarah P ^b   Casadevall, Arturo ^a  

^a ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

^b Department of Obstetrics Gynecology   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMPHOTERICIN B; FLUCONAZOLE; MANNAN; STEROL;

ANIMAL CELL; ANTIFUNGAL ACTIVITY; ARTICLE; CELL MEMBRANE; CELL STRUCTURE; CONTROLLED STUDY; CRYPTOCOCCOSIS; CRYPTOCOCCUS NEOFORMANS; CULTURE MEDIUM; DRUG EFFICACY; FUNGUS CULTURE; FUNGUS GROWTH; IMMUNITY; MACROPHAGE; MOUSE; NONHUMAN; PHAGOCYTOSIS; PRIORITY JOURNAL; SCANNING ELECTRON MICROSCOPY; ZETA POTENTIAL;

EID: 0033029684     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/aac.43.2.233     Document Type: Article

References (61)

1. Borowski, J., P. Jakoniuk, W. Jablonska, W. Jakubicz, and A. Szpak. 1974. The influence of antifungal antibiotics on some determinants of virulence in Candida albicans and Cryptococcus neoformans cells. Experientia 30:1210-1211.
2. Brajtburg, J., W. G. Powderly, G. Kobayashi, and G. Medoff. 1990. Amphotericin B: current understanding of mechanism of action. Antimicrob. Agents Chemother. 34:183-188.
3. Bulmer, G. S., M. D. Sans, and C. M. Gunn. 1976. Cryptococcus neoformans. I. Nonencapsulated mutants. J. Bacteriol. 94:1475-1479.
4. Casadevall, A., W. Cleare, M. Feldmesser, A. Glatman-Freedman, D. L. Goldman, T. R. Kozel, N. Lendvai, J. Mukhergee, L.-A. Pirofski, J. Rivera, A. L. Rosas, M. D. Scharff, P. Valadon, K. Westin, and Z. Zhong. 1998. Characterization of a murine monoclonal antibody to Cryptococcus neoformans polysaccharide that is a candidate for human therapeutic studies. Antimicrob. Agents Chemother. 42:1437-1446.
5. Casadevall, A., J. Mukherjee, and M. D. Scharff. 1992. Monoclonal antibody based ELISA for cryptococcal polysaccharide. J. Immunol. Methods 154:27-35.
6. Chan, J., V. Xing, R. S. Magliozzo, and B. R. Bloom. 1992. Killing of virulent Mycobacterium tuberculosis by reactive nitrogen intermediates produced by activated murine macrophages. J. Exp. Med. 175:1111-1122.
7. Chang, Y. C., and K. J. Kwon-Chung. 1994. Complementation of a capsule-deficient mutation of Cryptococcus neoformans restores its virulence. Mol. Cell. Biol. 14:4912-4919.
8. Cherniak, M. R., and J. B. Sundstrom. 1994. Polysaccharide antigens of the capsule of Cryptococcus neoformans. Infect. Immun. 62:1507-1512.
9. Cleare, W., and A. Casadevall. 1998. The different binding patterns of two immunoglobulin M monoclonal antibodies to Cryptococcus neoformans serotype A and D strains correlate with serotype classification and differences in functional assays. Clin. Diagn. Lab. Immunol. 5:125-129.
10. Collette, N., P. Van der Auwera, F. Meunier, C. Lambert, J. P. Sculier, and A. Coune. 1991. Tissue distribution and bioactivity of amphotericin B administered in liposomes to cancer patients. J. Antimicrob. Chemother. 27: 535-548.
11. Currie, B. P., and A. Casadevall. 1994. Estimation of the prevalence of cryptococcal infection among HIV infected individuals in New York City. Clin. Infect. Dis. 19:1029-1033.
12. Curtis, A. S. G. 1973. Cell adhesion. Prog. Biophys. Mol. Biol. 27:317-386.
13. Dealler, S. F. 1991. Antibiotics induce rapid bacterial zeta potential changes. J. Antimicrob. Chemother. 3:470-473.
14. Dismukes, W. E. 1993. Management of cryptococcosis. Clin. Infect. Dis. 17(Suppl. 2):507-512.
15. Drgonova, J., T. Drgon, K. Tanaka, R. Kollar, G.-C. Chen, R. A. Ford, C. S. M. Chan, Y. Takai, and E. Cabib. 1996. Rho 1p, a yeast protein at the interface between cell polarization and morphogenesis. Science 272:277-279.
16. Dromer, F., and J. Charreire. 1991. Improved amphotericin B activity by a monoclonal anti-Cryptococcus neoformans antibody: study during murine cryptococcosis and mechanisms of action. J. Infect. Dis. 163:1114-1120.
17. Dromer, F., S. Mathoulin, B. Dupont, L. Letenneur, and O. Ronin. 1996. Individual and environmental factors associated with infection due to Cryptococcus neoformans serotype D. French Cryptococcosis Study Group. Clin. Infect. Dis. 23:91-96.
18. Dugoni, B. M., B. J. Guglielmo, and H. Hollander. 1989. Amphotericin B concentrations in cerebral spinal fluid in patients with AIDS and cryptococcal meningitis. Clin. Pharmacol. 8:220-221.
19. Dykstra, M. A., L. Friedman, and J. W. Murphy. 1977. Capsule size of Cryptococcus neoformans: control and relationship to virulence. Infect. Immun. 16:129-135.
20. Franzot, S. P., and J. S. Hamdan. 1994. Effect of amphotericin B on the lipids of live different strains of Cryptococcus neoformans. Mycopathologia 128:85-89.
21. Franzot, S. P., J. Mukherjee, R. Cherniak, L. C. Chen, J. S. Hamdan, and A. Casadevall. 1998. Microevolution of a standard strain of Cryptococcus neoformans resulting in differences in virulence and other phenotypes. Infect. Immun. 66:89-97.
22. Fromtling, R. A., H. J. Shadomy, and E. S. Jacobson. 1982. Decreased virulence in stable, acapsular mutants of Cryptococcus neoformans. Mycopathologia 79:23-29.
23. Ghannoum, M. A., B. J. Spellberg, A. S. Ibrahim, J. A. Ritchie, B. Currie, E. D. Spitzer. J. E. J. Edwards, and A. Casadevall. 1994. Sterol composition of Cryptococcus neoformans in the presence and absence of fluconazole. Antimicrob. Agents Chemother. 38:2029-2033.
24. Goetz, P. J., and J. G. Penniman, Jr. 1976. A new technique for microelectrophoretic measurements. Am. Lab. 1976:212-230.
25. Ikada, Y., and Y. Tabata. 1986. Phagocytosis of bioactive microspheres. J. Bioactive Compatible Polymers 1:32-46.
26. Ikeda, R., T. Shinoda, K. Kagaya, and Y. Fukazawa. 1984. Role of serum factors in the phagocytosis of weakly or heavily encapsulated Cryptococcus neoformans strains by guinea pig peripheral blood leukocytes. Microbiol. Immunol. 28:51-61.
27. Illum, L., L. O. Jacobson, R. H. Muller, E. Mak, and S. S. Davis. 1987. Surface characteristics and the interaction of colloidal particles with mouse peritoneal macrophages. Biomaterials 8:113-117.
28. Jacobson, E. S., and S. B. Tinnell. 1993. Antioxidant function of fungal melanin. J. Bacteriol. 175:7102-7104.
29. Kawaguchi, H., N. Koiwai, Y. Ohtsuka, N. Miyamoto, and S. Sasakawa. 1986. Phagocytosis of laxex particles by leukocytes. I. Dependence of phagocytosis on the size and surface potentials of particles. Biomaterials 7:61-66.
30. Kozel, T. R., B. C. deJong, M. M. Grinsell, R. S. MacGill, and K. K. Wall. 1998. Characterization of anticapsular monoclonal antibodies that regulate activation of the complement system by the Cryptococcus neoformans capsule. Infect. Immun. 66:1538-1546.
31. Kozel, T. R., and E. C. Gotschlich. 1982. The capsule of Cryptococcus neoformans passively inhibits phagocytosis of the yeast by macrophages. J. Immunol. 129:1675-1680.
32. Kozel, T. R., and C. A. Hermerath. 1984. Binding of cryptococcal polysaccharide to Cryptococcus neoformans. Infect. Immun. 43:879-886.
33. Kozel, T. R., E. Reiss, and R. Cherniak. 1980. Concomitant but not causal association between surface charge and inhibition of phagocytosis by cryptococcal polysaccharide. Infect. Immun. 29:295-300.
34. Kwon-Chung, K. J., and J. C. Rhodes. 1986. Encapsulation and melanin formation as indicators of virulence in Cryptococcus neoformans. Infect. Immun. 51:218-223.
35. Louria, D. B. 1958. Some aspects of the absorption, distribution, and excretion of amphotericin B in man. Amibiot. Med. Clin. Ther. 5:295-301.
36. Mitchell, T. G., and J. R. Perfect. 1995. Cryptococcus in the era of AIDS -100 years after the discovery of Cryptococcus neoformans. Clin. Microbiol. Rev. 8:515-548.
37. Miyake, Y., T. Tsunoda, S. Minagi, Y. Akagawa, H. Tsuru, and H. Suginaka. 1990. Antifungal drugs affect adherence of Candida albicans to acrylic surfaces by changing the zeta-potential of fungal cells. FEMS Microbiol. Lett. 69:211-214.
38. Mozaffarian, N., J. W. Berman, and A. Casadevall. 1997. Enhancement of nitric oxide synthesis by macrophages represents an additional mechanism of action for amphotericin B. Antimicrob. Agents Chemother. 41:1825-1829.
39. Mozaffarian, N., J. W. Berman, and A. Casadevall. 1995. Immune complexes increase nitric oxide production by interferon-gamma-stimulated murine macrophage-like J774. 16 cells. J. Leukoc. Biol. 57:657-662.
40. Mukherjee, J., M. Feldmesser, M. D. Scharff, and A. Casadevall. 1995. Monoclonal antibodies to Cryptococcus neoformans glucuronoxylomannan enhance fluconazole efficacy. Antimicrob. Agents Chemother. 39:1398-1405.
41. Mukherjee, J., L. S. Zuckier, M. D. Scharff, and A. Casadevall. 1994. Therapeutic efficacy of monoclonal antibodies to Cryptococcus neoformans glucuronoxylomannan alone and in combination with amphotericin B. Antimicrob. Agents Chemother. 38:580-587.
42. Muratsugu, M., Y. Miyake, N. Ishida, A. Hyodo, and K. Terayama. 1995. Decrease in surface charge density of Klebsiella pneumoniae treated with cefodizime and enhancement of phagocytic function of polymorphonuclear lymphocytes stimulated by the drug-treated bacteria. Biol. Pharm. Bull. 18: 1259-1263.
43. Nagura, H., J. Asai, Y. Katsumata, and K. Kojima. 1973. Role of electric surface charge of cell membrane in phagocytosis. Acta Pathol. Jpn. 23:279-290.
44. Nassar, F., E. Brummer, and D. A. Stevens. 1995 Different components in human serum inhibit multiplication of Cryptococcus neoformans and enhance fluconazole activity. Antimicrob. Agents Chemother. 39:2490-2493. (Erratum, 40:1330, 1996.)
45. National Committee for Clinical Laboratory Standards. 1992. Reference method for broth dilution antifungal susceptibility testing for yeasts. Proposed standard M27-P. National Committee for Clinical Laboratory Standards, Wayne, Pa.
46. Nguyen, M. H., C. J. Clancy, V. L. Yu, V. C. Yu, A. J. Morris, D. R Snydman, D. A. Sutton, and M. G. Rinaldi. 1998. Do in vitro susceptibility data predict the microbiologic response to amphotericin B? Results of a prospective study of patients with Candida fungemia. J. Infect. Dis. 177:425-430.
47. Nosanchuk, J., and A. Casadevall. 1997. Cellular charge of Cryptococcus neoformans: contributions from the capsular polysaccharide, melanin, and monoclonal antibody binding. Infect. Immun. 65:1836-1841.
48. Ohtomo, T., Y. Ohshima, Y. Usui, Y. Ichiman, N. Yanagisawa, E. Yokota, and J. Shimada. 1995. Effect of sub-inhibitory concentrations of clarithromycin and erythromycin on the production of Staphylococcus aureus capsules. J. Chemother. 7(Suppl. 4):9-11.
49. Ramadan, M. A., A. F. Tawfik, A. M. Shibl, and C. G. Gemmell. 1995. Postantibiotic effect of azithromycin and erythromycin on streptococcal susceptibility to phagocytosis. J. Med. Microbiol. 42:362-366.
50. Richmond, D. V., and D. J. Fisher. 1973 The electrophoretic mobility of microorganisms. Adv. Microb. Physiol. 9:1-29.
51. Saag, M. S., and W. E. Dismukes. 1988. Azole antifungal agents: emphasis on new triazoles. Antimicrob. Agents Chemother. 32:1-8.
52. Sengar, A. S., N. A. Markley, N. J. Marini, and D. Young. 1997. Mkhl, a MEK kinase required for cell wall integrity and proper response to osmotic and temperature stress in Schizosaccharomyces pombe. Mol. Cell. Biol. 17: 3508-3519.
53. Small, J. M., and T. G. Mitchell. 1989. Strain variation in antiphagocytic activity of capsular polysaccharides from Cryptococcus neoformans serotype A. Infect. Immun. 57:3751-3756.
54. Spitzer, E. D., S. G. Spitzer, L. F. Freundlich, and A. Casadevall. 1993. Persistence of the initial infection in recurrent cryptococcal meningitis. Lancet 341:595-596.
55. Tabata, Y., and Y. Ikada. 1988. Effect of size and surface charge of polymer microspheres on their phagocytosis by macrophages. Biomaterials 9:356-361.
56. Tohyama, M., K. Kawakami, and A. Saito. 1996. Anticryptococcal effects of amphotericin B is mediated through macrophage production of nitric oxide. Antimicrob. Agents Chemother. 40:1919-1923.
57. Wilson, E., L. Thorson, and D. P. Speert. 1991. Enhancement of macrophage superoxide anion production by amphotericin B. Antimicrob. Agents Chemother. 35:796-800.
58. Wolf, J. E., and S. E. Massof. 1990. In vivo activation of macrophage oxidative burst activity by cytokines and amphotericin B. Infect. Immun. 58:1296-1300.
59. Yamaguchi, H., S. Abe, and Y. Tokuda. 1993. Immunomodulating activity of antifungal drugs. Ann. N. Y. Acad. Sci. 685:447-457.
60. Yasuoka, A., S. Kohno, H. Yamada, M. Kaku, and H. Koga. 1994. Influence of molecular sixes of Cryptococcus neoformans capsular polysaccharide on phagocytosis. Microbiol. Immunol. 38:851-856.
61. Zuger, A., E. Louie, R. S. Holzman, M. S. Simberkoff, and J. J. Rahal. 1986. Cryptococcal disease in patients with the acquired immunodeficiency syndrome: diagnostic features and outcome of treatment. Ann. Intern. Med. 104:234-240.